Interpretation of the Major Updates of Guidelines Regarding Hyperuricemia and Gout in Chronic Kidney Disease

doi:10.12114/j.issn.1007-9572.2021.00.573

Abstract

Abstract: The incidence of hyperuricemia（HUA）and gout is increasing significantly，and tends to occur at an early age with the social development and changes in patterns of life. HUA has become the second leading metabolic disease following diabetes mellitus，which is not only a common complication of chronic kidney disease（CKD），but also an important risk factor for CKD. The guidelines for the diagnosis and treatment of HUA and gout have been updated to accommodate newly emerging evidence. We interpreted the essentials of new updates regarding HUA and gout in CKD on the basis of research evidence，including the indication of initial urate-lowering therapy，selection of pharmacologic urate-lowering therapy，gout flare management，alkalinizing urine and use of vitamin C on the basis of research evidence，hoping to provide clinicians with supports for delivering comprehensive and individual therapies.

Key words: Kidney diseases, Hyperuricemia, Gout, Guidebook, Therapy

摘要： 随着社会发展及人们生活方式的改变，高尿酸血症（HUA）与痛风的发病率显著上升，并有年轻化趋势。目前HUA已成为仅次于糖尿病的第二大代谢性疾病，其不仅是慢性肾脏病（CKD）的常见并发症，而且是导致CKD发生和发展的重要原因。基于新的研究证据，国内外有关HUA与痛风诊治指南不断更新，并提出较多新观点。本文主要从CKD角度对国内外有关HUA与痛风的指南更新要点进行解读，并结合相关研究证据从初始降尿酸治疗指征、降尿酸治疗药物的选择、痛风急性发作的管理、碱化尿液、维生素C的使用方面进行分析和探讨，旨在为临床综合性、个体化治疗提供借鉴和帮助。

关键词: 肾疾病, 高尿酸血症, 痛风, 指南, 治疗

WANG Xu,LUO Dongping,RU Yanhai, et al. Interpretation of the Major Updates of Guidelines Regarding Hyperuricemia and Gout in Chronic Kidney Disease　[J]. Chinese General Practice, 2021, 24(33): 4191-4195. DOI: 10.12114/j.issn.1007-9572.2021.00.573.
王旭,罗冬平,茹彦海等. 从慢性肾脏病角度看高尿酸血症与痛风的指南更新要点[J]. 中国全科医学, 2021, 24(33): 4191-4195. DOI: 10.12114/j.issn.1007-9572.2021.00.573.

References

［1］易凤，姜俊，兰雷，等．IgA肾病患者高尿酸血症的相关因素分析［J］．中华肾脏病杂志，2019，35（11）：816-821．DOI：10.3760/cma.j.issn.1001-7097.2019.11.003.
YI F，JIANG J，LAN L，et al．Related factors of hyperuricemia in IgA nephropathy patients［J］．Chin J Nephrol，2019，35（11）：816-821．DOI：10.3760/cma.j.issn.1001-7097.2019.11.003.
［2］CHANG Y H，LEI C C，LIN K C，et al．Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus——a 4.6-year cohort study［J］．Diabetes Metab Res Rev，2016，32（6）：557-564．DOI：10.1002/dmrr.2768.
［3］ZUO T，JIANG L，MAO S，et al．Hyperuricemia and contrast-induced acute kidney injury：a systematic review and meta-analysis［J］．Int J Cardiol，2016，224：286-294．DOI：10.1016/j.ijcard.2016.09.033.
［4］FITZGERALD J D，DALBETH N，MIKULS T，et al．2020 American College of Rheumatology guideline for the management of gout［J］．Arthritis Care Res（Hoboken），2020，72（6）：744-760．DOI：10.1002/acr.24180.
［5］中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南（2019）［J］．中华内分泌代谢杂志，2020，36（1）：1-13．DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
Chinese Society of Endocrinology，Chinese Medical Association.Guideline for the diagnosis and management of hyperuricemia and gout in China（2019）［J］．Chin J Endocrinol Metab，2020，36（1）：1-13．DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
［6］高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识［J］．中华内科杂志，2017，56（3）：235-248．DOI：10.3760/cma.j.issn.0578-1426.2017.03.021.
Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases.Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases［J］．Chin J Intern Med，2017，56（3）：235-248．DOI：10.3760/cma.j.issn.0578-1426.2017.03.021.
［7］NAKAYA I，NAMIKOSHI T，TSURUTA Y，et al．Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists：a questionnaire survey［J］．Nephrology（Carlton），2011，16（5）：518-521．DOI：10.1111/j.1440-1797.2011.01446.x.
［8］CHA R H，KIM S H，BAE E H，et al．Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease：a questionnaire survey［J］．Kidney Res Clin Pract，2019，38（3）：373-381．DOI：10.23876/j.krcp.19.007.
［9］KIMURA K，HOSOYA T，UCHIDA S，et al．Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia：a randomized trial［J］．Am J Kidney Dis，2018，72（6）：798-810．DOI：10.1053/j.ajkd.2018.06.028.
［10］王惠芳，张伟，李宁，等．非布司他治疗慢性肾脏病3~5期伴高尿酸血症患者的疗效分析及对肾功能的影响［J］．中华肾脏病杂志，2017，33（10）：721-728．DOI：10.3760/cma.j.issn.1001-7097.2017.10.001.
WANG H F，ZHANG W，LI N，et al．The urate- lowering efficacy of febuxostat and its effect on renal function in hyperuricemic patients with chronic kidney disease stages 3-5［J］．Chinese Journal of Nephrology，2017，33（10）：721-728．DOI：10.3760/cma.j.issn.1001-7097.2017.10.001.
［11］GONZALEZ-GALARZA F F，TAKESHITA L Y，SANTOS E J，et al．Allele frequency net 2015 update：new features for HLA epitopes，KIR and disease and HLA adverse drug reaction associations［J］．Nucleic Acids Res，2015，43（Database issue）：D784-788．DOI：10.1093/nar/gku1166.
［12］WHITE W B，SAAG K G，BECKER M A，et al．Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］．N Engl J Med，2018，378（13）：1200-1210．DOI：10.1056/nejmoa1710895.
［13］UCHIDA S，SHIMADA K，MISAKA S，et al．Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes［J］．Drug Metab Pharmacokinet，2010，25（6）：605-610．DOI：10.2133/dmpk.dmpk-10-nt-040.
［14］STAMP L K，TAYLOR W J，JONES P B，et al．Starting dose is a risk factor for allopurinol hypersensitivity syndrome：a proposed safe starting dose of allopurinol［J］．Arthritis Rheum，2012，64（8）：2529-2536．DOI：10.1002/art.34488.
［15］PAISANSINSUP T，BREITENSTEIN M K，SCHOUSBOE J T.Association between adverse reactions to allopurinol and exposures to high maintenance doses：implications for management of patients using allopurinol［J］．J Clin Rheumatol，2013，19（4）：180-186．DOI：10.1097/RHU.0b013e31829372e6.
［16］TSURUTA Y，NITTA K，AKIZAWA T，et al．Association between allopurinol and mortality among Japanese hemodialysis patients：results from the DOPPS［J］．Int Urol Nephrol，2014，46（9）：1833-1841．DOI：10.1007/s11255-014-0731-0.
［17］BECKER M A，SCHUMACHER H R，ESPINOZA L R，et al．The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout：the CONFIRMS trial［J］．Arthritis Res Ther，2010，12（2）：R63．DOI：10.1186/ar2978.
［18］CHEN C H，CHEN C B，CHANG C J，et al．Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in asians：a population-based cohort study and meta-analysis［J］．Clin Pharmacol Ther，2019，106（2）：391-401．DOI：10.1002/cpt.1377.
［19］中国慢性肾脏病患者合并高尿酸血症诊治共识专家组.中国慢性肾脏病患者合并高尿酸血症诊治专家共识［J］．中华肾脏病杂志，2017，33（6）：463-469．DOI：10.3760/cma.j.issn.1001-7097.2017.06.012.
［20］陆世凯.不同剂量秋水仙碱治疗痛风性关节炎患者的临床效果比较［J］．中华全科医学，2017，15（10）：1700-1703．DOI：10.16766/j.cnki.issn.1674-4152.2017.10.019.
LU S K.Clinical effect of the different dosage of colchicine on 98 cases of gouty arthritis［J］．Chinese Journal of General Practice，2017，15（10）：1700-1703．DOI：10.16766/j.cnki.issn.1674-4152.2017.10.019.
［21］STAMP L K，O'DONNELL J L，FRAMPTON C，et al．Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout：a pilot randomized controlled trial［J］．Arthritis Rheum，2013，65（6）：1636-1642．DOI：10.1002/art.37925.
［22］FERRARO P M，CURHAN G C，GAMBARO G，et al．Total，dietary，and supplemental vitamin C intake and risk of incident kidney stones［J］．Am J Kidney Dis，2016，67（3）：400-407．DOI：10.1053/j.ajkd.2015.09.005.
［23］BINIAZ V，TAYEBI A，EBADI A，et al．Effect of vitamin C supplementation on serum uric acid in patients undergoing hemodialysis：a randomized controlled trial［J］．Iran J Kidney Dis，2014，8（5）：401-407.
［24］吴书涛，陆奎英，张敏，等．维生素C对3种不同厂家试剂血尿酸检测结果的影响［J］．国际检验医学杂志，2017，38（8）：1106-1107．DOI：10.3969/j.issn.1673-4130.2017.08.038.
［25］TAYLOR T H，MECCHELLA J N，LARSON R J，et al．Initiation of allopurinol at first medical contact for acute attacks of gout：a randomized clinical trial［J］．Am J Med，2012，125（11）：1126-1134.e7．DOI：10.1016/j.amjmed.2012.05.025.

[1]	ZHANG Peng, GAO Ying, YANG Hongxi, WAN Chunxiao. Association between Serum Uric Acid Level and the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(31): 3884-3889.
[2]	HE Yingmei, JIA Xue, ZHU Guojun, LIU Bing. Effect of Serum Uric Acid Longitudinal Trajectory on New-onset Hypertriglyceridemia: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(29): 3636-3639.
[3]	SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua. Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence [J]. Chinese General Practice, 2023, 26(26): 3220-3229.
[4]	WANG Rui, WANG Xiaomei, PENG Guoqing, YU Huan, WANG Sihan, XIA Jin. Screening Assessment and Therapy Intervention of Cancer Cachexia in Adult Patients——Based on the Interpretation of Cancer Cachexia in Adult Patients: ESMO Clinical Practice Guidelines [J]. Chinese General Practice, 2023, 26(23): 2823-2829.
[5]	ZHU Danmeng, HUANG Yuying, LUO Tong'an, HE Changyuan, CHEN Rilan. Effect of Pricking-bloodletting Therapy Combined with Zhuang-medicine-thread Moxibustion on TLRs/MyD88 Signal Pathway in a Rat Model of Acute Gouty Arthritis [J]. Chinese General Practice, 2023, 26(20): 2525-2531.
[6]	China Gerontological Nursing Alliance, Xiang Ya Nursing School (Xiangya Oceanwide Health Management Research Institute of Central South University), Xiangya Hospital Central South University (National Clinical Research Center for Geriatric Disorders), Beijing Hospital (National Center for Gerontology, National Clinical Research Center for Geriatric Disorders), ZENG Xianmei, HU Mingyue, FENG Hui. Clinical Practice Guideline on Non-pharmacological Interventions for Older Adults with Cognitive Dysfunction: Physical Activity [J]. Chinese General Practice, 2023, 26(16): 1927-1937,1971.
[7]	SONG Hualong, GAO Ying. Association between Serum Uric Acid and the Risk of Type 2 Diabetes Mellitus: a Population-based Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(15): 1831-1839.
[8]	XIN Jiadong, ZHOU Jiabao, WU Zhiyuan, ZHANG Xuming, GAO Jiandong. Advances in Urate Excretion and Urate Transporters in Hyperuricemia [J]. Chinese General Practice, 2023, 26(15): 1916-1922.
[9]	National Center of Gerontology, Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, Imaging Group of Cardiovascular Department, Beijing Medical Association, Chinese Medical and Health Culture Association Cardiovascular Health and Science Sports Branch of China Health Culture Association. Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition) [J]. Chinese General Practice, 2023, 26(14): 1692-1702.
[10]	YAO Huijuan, YANG Yu, XU Ajing. Interpretation of Diabetes Management in Chronic Kidney Disease: a Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) [J]. Chinese General Practice, 2023, 26(12): 1415-1421.
[11]	LIU Yanhui, CHEN Shuchun. Interpretation and Clinical Significance of the Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement [J]. Chinese General Practice, 2023, 26(12): 1422-1428.
[12]	WANG Junwei, LIN Lingjun, SONG Linling, CHENG Xiaocui, NIE Xiuling. Association between Serum Potassium and Metabolic-associated Fatty Liver Disease in Patients with Primary Gout [J]. Chinese General Practice, 2023, 26(12): 1479-1484.
[13]	YAN Peng, SONG Jianling, FANG Xiangdong. Recent Developments in Parathyroid Hormone Type 1 Receptor and Kidney Disease [J]. Chinese General Practice, 2023, 26(11): 1398-1403.
[14]	WANG Xixi, SHEN Rui, WANG Junjie, XU Niying. Best Evidence Summary of Exercise Interventions for Osteoporosis in Postmenopausal Women [J]. Chinese General Practice, 2023, 26(09): 1151-1158.
[15]	LIU Lanping, YANG Yue, HUANG Man, MA Xiaojing, YE Yongming, LIU Xiaoxu, LIN Huize, ZHU Kexin, GUO Shengnan, FEI Yutong, YANG Tao, YU Jinna. Identification of Clinical Questions for the Development of Clinical Practice Guideline on Acupuncture and Moxibustion for Nonspecific Low Back Pain Using the Modified Delphi Method [J]. Chinese General Practice, 2023, 26(09): 1037-1043.